Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
BMJ Open|March 23, 2019
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocolY K Onno Teng, Ian N Bruce, Betty Diamond, et al.
Rheumatology (Oxford, England)|October 19, 2017
Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder indexKenneth C Kalunian, Murray B Urowitz, David Isenberg, et al.
Lupus Science & Medicine|December 28, 2018
Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC studyRonald F van Vollenhoven, William Stohl, Richard A Furie, et al.
Arthritis and Rheumatism|June 7, 2013
Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III studyEduardo F Mysler, Alberto J Spindler, Renato Guzman, et al.
Lupus Science & Medicine|January 24, 2025
Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)Martin Aringer, Laurent Arnaud, Richard A Furie, et al.
Annals of the Rheumatic Diseases|March 26, 2022
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trialsEdward M Vital, Joan T Merrill, Eric F Morand, et al.
Annals of the Rheumatic Diseases|May 17, 2022
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trialsIan N Bruce, Richard A Furie, Eric F Morand, et al.
ACR Open Rheumatology|July 26, 2026
Anifrolumab Plus Standard of Care Reduces Long-Term Cardiovascular Damage in Adults With Systemic Lupus Erythematosus: Findings From a Real-World External Control StudyZahi Touma, Ian N Bruce, Richard A Furie, et al.
The New England Journal of Medicine|September 7, 2022
Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus ErythematosusRichard A Furie, Ronald F van Vollenhoven, Kenneth Kalunian, et al.
Annals of the Rheumatic Diseases|October 7, 2021
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trialRichard A Furie, Gustavo Aroca, Matthew D Cascino, et al.
Pageof 8